Phase IV PROVE study: Perampanel in real-world clinical care of pediatric patients with epilepsy

CONCLUSIONS: Perampanel was generally well tolerated with <21% of TEAEs leading to withdrawal at 24 months, had favorable retention rates (≥50% and >35% at 12 and 24 months, respectively), and sustained efficacy in pediatric patients during routine clinical care.PMID:38569352 | DOI:10.1016/j.ejpn.2024.02.008
Source: European Journal of Paediatric Neurology - Category: Neurology Authors: Source Type: research